Taysha Gene Therapies Q1 Earnings Call Highlights

Taysha Gene Therapies NASDAQ: TSHA executives highlighted regulatory progress, ongoing clinical enrollment, and manufacturing preparations for its Rett syndrome gene therapy candidate TSHA-102 during the company’s first-quarter 2026 earnings call, while also reporting a wider year-over-year net loss driven by increased development and manufacturing activity.

Regulatory discussions focus on potential interim-data BLA pathway

CEO Sean Nolan said the company recently held its initial Breakthrough Therapy Type B multidisciplinary meeting with the FDA, where the parties “reaffirmed alignment on the planned pathway toward a BLA submission for TSHA-102,” including pivotal trial design, endpoints, and “BLA submission scenarios, including the potential to submit for approval based on a six-month interim analysis from the REVEAL pivotal trial.”

Nolan described the agency’s position as dependent on the “totality of the evidence,” adding that FDA feedback left “the door…open” to an approval submission based on six-month data, while acknowledging the agency’s typical preference for 12 months of gene therapy follow-up. He also said Taysha would consider approaches such as a rolling review if the FDA ultimately preferred longer follow-up, given that CMC and other modules could be submitted earlier.

In response to investor questions, Nolan reiterated that the company’s preferred scenario is “a full approval at six months worth of data,” but he emphasized the decision would be “won by the data.”

Manufacturing: PPQ campaign underway with comparability discussions

Nolan said the company held a Type C meeting with the FDA in the first quarter, during which the FDA endorsed Taysha’s proposed process performance qualification (PPQ) campaign strategy to support a planned BLA. The company initiated the “BLA-enabling PPQ campaign” in April and expects to complete execution by the fourth quarter of 2026.

Nolan also noted that the FDA previously agreed TSHA-102 material produced from clinical and final commercial manufacturing processes is comparable, which he said “may support our ability to utilize the clinical data across all clinical studies” in a future BLA submission. In Q&A, he said comparability has been supported across multiple manufacturing runs and that additional PPQ runs are in progress.

On manufacturing redundancy, CFO Kamran Alam said TSHA-102 is being made at Catalent’s Baltimore facility, which he said has been inspected and has “extensive gene therapy manufacturing experience.” Alam added that the company will evaluate downstream redundancy closer to a potential BLA submission to mitigate supply-chain disruption risk.

Clinical update: Dosing continues in REVEAL pivotal and ASPIRE trials

Nolan said Taysha has continued dosing in the REVEAL pivotal trial across multiple sites and that enrollment in the ASPIRE trial is ongoing, with the company “on track to complete dosing in both trials this quarter.” He added that as of a May 2026 data cutoff, both high- and low-dose TSHA-102 “continue to be generally well-tolerated,” with “no treatment-related serious adverse events or dose-limiting toxicities observed” across patients treated in the REVEAL phase I/II and pivotal studies.

The company also previewed a longer-term data update expected later in the second quarter. Nolan said Taysha plans to report longer-term data from all 12 pediatric, adolescent, and adult patients treated in Part A of the REVEAL Phase I/II trial, including “at least 12 months of data from all 12 patients treated with TSHA-102.” He said the update is expected to include functional gains measured by natural history-defined developmental milestones, along with additional functional improvements meaningful to caregivers and clinicians.

Management also discussed how Part A milestone outcomes are evaluated, emphasizing a three-part approach that includes caregiver completion of a clinician-administered historical milestone questionnaire (used to determine whether a milestone is eligible for gain/regain), post-treatment video documentation, and independent evaluation by multiple external raters using predefined milestone definitions from the pivotal protocol.

Nolan reiterated previously presented Part A results, stating the company last year reported an 83% response rate at six months post-treatment among high-dose patients, rising to 100% at nine months in the six high-dose patients. He added that across 10 treated patients, Taysha observed 22 developmental milestones gained, as well as 165 additional functional skills and improvements across core Rett syndrome domains—an average of about 19 functional gains per patient.

In Q&A, Nolan said Part B uses a similar, video-based approach, with central adjudication by independent raters. He said the primary difference is a “standalone assessment of all of the milestones” in Part B, which he suggested could improve capture of milestone changes compared to Part A.

Preclinical publications and upcoming ASGCT presentation

President and Head of R&D Sukumar Nagendran discussed recently published preclinical data in Frontiers in Medicine, Gene & Cell Therapy, which he said supported the minimally invasive intrathecal route of administration. According to Nagendran, the data showed intrathecal and direct-to-brain intracisterna magna administration resulted in “comparable, consistent, and widespread distribution of AAV9 vector throughout the brain and spinal cord in non-human primates.”

Nagendran also said Taysha plans to present additional preclinical data on May 14 at the ASGCT 2026 annual meeting. He said the company’s self-complementary AAV9 vector demonstrated “significantly higher protein expression” than single-stranded AAV9 in neuronal mouse cell models, including “30-fold higher transduction efficiency,” and that the miniMECP2 protein used in TSHA-102 was “functionally comparable to the full-length MECP2 protein across molecular and biochemical functions.”

Responding to an analyst question, Nolan said the company aimed to connect construct design to clinical observations, including rapid and deepening functional improvements. Nagendran added that self-complementary constructs “turn on very quickly” in the CNS and said the company has seen early impacts in autonomic dysfunction “usually within a couple of weeks post-dosing,” based on Part A observations described on the call.

Financial results: Higher R&D spend and wider net loss

Alam reported first-quarter 2026 R&D expenses of $33.8 million, up from $15.6 million in the first quarter of 2025, driven primarily by BLA-enabling PPQ manufacturing initiatives and higher clinical expenses across the REVEAL and ASPIRE trials, along with increased compensation tied to additional R&D headcount.

General and administrative expenses were $9.7 million, compared with $8.2 million a year earlier, which Alam attributed to higher compensation and increased consulting and professional fees, including commercial launch readiness initiatives.

Net loss was $42.4 million, or $0.12 per share, compared with a net loss of $21.5 million, or $0.08 per share, in the year-ago quarter. As of March 31, 2026, Taysha reported $276.6 million in cash and cash equivalents, and Alam said the company expects its current cash resources to fund planned operating expenses “into 2028.”

Nolan said Taysha continues building internal commercial infrastructure and expects to share additional commercial planning details in the second half of 2026. He added that market research indicates clinicians and caregivers prefer intrathecal administration due to familiarity and scalability compared with direct-to-brain delivery, and he described TSHA-102 administration as a roughly “20-minute lumbar puncture” that can be completed with mild or no sedation.

About Taysha Gene Therapies NASDAQ: TSHA

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.